Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection. | Ann Oncol;28(3): 441-443, 2017 03 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection.

Curigliano, G; Goldhirsch, A.

Affiliation

Curigliano G; Giuseppe Curigliano and Carmen Criscitiello, Istituto Europeo di Oncologia, Milano, Italy.
Goldhirsch A; European Institute of Oncology, Milan, Italy.

Ann Oncol ; 28(3): 441-443, 2017 03 01.

Article in En | MEDLINE | ID: mdl-28426119

Subject(s)

Antibodies, Monoclonal, Humanized; Breast Neoplasms; Humans; Patient Selection; Trastuzumab

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Affiliation country: Italy Country of publication: United kingdom

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Document type: Article Affiliation country: Italy Country of publication: United kingdom